Clinical Trial Update: A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Sacituzumab Tirumotecan (MK-2870) in advanced/metastatic gastroesophageal adenocarcinoma is currently active but not recruiting (MK-2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Adenocarcinoma
• Gastroesophageal Cancer

Drugs mentioned

• Sacituzumab Tirumotecan (Sacituzumab govitecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Gastroesophageal Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING